Yijing Shen

Atezolizumab for First‐Line Treatment of Metastatic Nonsquamous NSCLC

Federico Cappuzzo, M. Socinski, F. Cappuzzo, 2018, The New England journal of medicine.

Overall survival (OS) analysis of IMpower150, a randomized Ph 3 study of atezolizumab (atezo) + chemotherapy (chemo) ± bevacizumab (bev) vs chemo + bev in 1L nonsquamous (NSQ) NSCLC.

M. Socinski, F. Cappuzzo, D. Moro-Sibilot, 2018 .

LBA1_PRPrimary PFS and safety analyses of a randomized phase III study of carboplatin + paclitaxel +/− bevacizumab, with or without atezolizumab in 1L non-squamous metastatic nsclc (IMPOWER150)

M. Socinski, D. Moro-Sibilot, F. Barlesi, 2017 .

Abstract B49: GRN1005 phase I studies: Final results.

T. Mikkelsen, P. Wen, S. Rosenfeld, 2011 .

Chemotherapeutic Response and Prognosis among Lung Cancer Patients with and without Depression

Yayun Qian, Yao-dong Zhu, Yanqing Liu, 2015, Journal of Cancer.

Enhancing Hyper-Hypothermia Integration Therapy ( HIT ) Antitumor Effect with Toll-Like Receptor 7 Agonist

Huixian Lin, Yijing Shen, Chia-Hsuan Chou, 2022 .